BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting
PITTSBURGH, PA, March 15, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., hematologist/oncologist at UPMC Hillman Cancer Center and Assistant Professor, Division of Hematology-Oncology and of Immunology […]
